Angiopoietin and Adverse Outcomes in Cardiac Surgery (ANGE)

Centre Hospitalier Universitaire, Amiens

Status: Enrolling

Conditions: Cardiac Surgery; Acute Kidney Injury

Treatments: Other: blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT05817929

PI2023_843_0015

Details and patient eligibility

About

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.

The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patient scheduled for cardiac surgery under cardiopulmonary bypass

Exclusion criteria

• patient less than 18 years old,
• redo surgery,
• urgent surgery,
• endocarditis,
• aortic root repair surgery
• aortic dissection
• heart beating surgery,
• heart transplantation

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

cardiac surgery

Experimental group

Treatment:

Other: blood sample